Article
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Diabetes - 1 Jul 1999
Brown K K, Henke B R, Blanchard S G, Cobb J E, Mook R, Kaldor I, Kliewer S A, Lehmann J M, Lenhard J M, Harrington W W, Novak P J, Faison W, Binz J G, Hashim M A, Oliver W O, Brown H R, Parks D J, Plunket K D, Tong W Q, Menius J A, Adkison K, Noble S A, Willson T M
Abstract excerpt
The discovery that peroxisome proliferator-activated receptor (PPAR)-gamma was the molecular target of the thiazolidinedione class of antidiabetic agents suggested a key role for PPAR-gamma in the regulation of carbohydrate and lipid metabolism. Through the use of high-throughput biochemical assays, GW1929, a novel N-aryl tyrosine activator of human PPAR-gamma, was identified. Chronic oral administration of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.